The trigeminal neuralgia therapeutics market was valued at $56.7m in 2011, and is forecast to grow at a compound annual growth rate (CAGR) of 3.2% over the next eight years to reach $72.9m by 2019.
Trigeminal neuralgia therapeutics market growth is set to be predominantly driven by the increasing patient pool due to growing elderly populations.
Trigeminal neuralgia, often described as one of the most painful conditions with which to live, is primarily caused by the compression of the fifth cranial nerve (trigeminal nerve), which results in exacerbation and remission of severe facial pain.
Trigeminal neuralgia becomes more common in old age, and the condition is chronic and incurable. Therefore, long-term medical treatment is demanded for the symptomatic relief of the intense and frequent bouts of facial pain.
The slow progression experienced by the trigeminal neuralgia therapeutics market throughout 2006 to 2011 can be attributed to the dominance of generic drugs and the associated low cost of therapy.
This lack of growth is expected to continue through the remainder of the decade, primarily due to the presence of generics and lack of pipeline activity.
The majority of drugs currently available within the trigeminal neuralgia therapeutics market are generic, have a low cost of therapy, and offer good short-term efficacy and safety.
However, long-term side effects include constipation, memory loss, drowsiness, dizziness, and involuntary eye and muscle movements. Patients can also develop drug resistance from long-term use.
For more information on the trigeminal neuralgia therapeutics market, see the latest research: Trigeminal Neuralgia Therapeutics Market Report
Follow us on Twitter @CandMResearch
Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.